Armando Anido - Jan 31, 2023 Form 4 Insider Report for Zynerba Pharmaceuticals, Inc. (ZYNE)

Role
Chairman & Chief Exec. Officer, Director
Signature
/s/ Albert P. Parker, Attorney-in-Fact
Stock symbol
ZYNE
Transactions as of
Jan 31, 2023
Transactions value $
-$6,979
Form type
4
Date filed
2/2/2023, 07:13 PM
Previous filing
Jan 25, 2023
Next filing
Feb 9, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZYNE Common Stock Award +42.4K +5.14% 869K Jan 31, 2023 Direct F1
transaction ZYNE Common Stock Tax liability -$6.98K -11.7K -1.35% $0.60 857K Feb 1, 2023 Direct F2
holding ZYNE Common Stock 26.6K Jan 31, 2023 See footnote F3
holding ZYNE Common Stock 13.3K Jan 31, 2023 See footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock award was granted in lieu of a portion of a cash bonus earned by the Reporting Person and fully vested as of the grant date.
F2 This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.
F3 TUA of Armando Anido and Nancy J. Anido Trusts are controlled by Armando Anido, who has voting and dispositive power with respect to shares held by the trusts.